TerminatedNCT06011577
Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD
Medication studyAges 18–65United StatesDepression
Understand this study
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Dothan and 35 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: August 17, 2023
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 27
- Sponsor
- Levomecor Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06011577
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as an Adjunctive Treatment for Major Depressive Disorder (RELIGHT)
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Dothan · Homewood · Anaheim
32 more locations
- Lafayette
- Newport Beach
- Orange
- Redlands
- Sherman Oaks
- Farmington
- Brandon
- Hialeah
- Jacksonville
- Miami
- Okeechobee
- Tampa
- Springfield
- Baltimore
- Mankato
- Toms River
- Brooklyn
- Cedarhurst
- New York
- Philadelphia
- Franklin
- Memphis
- Austin
- Bellaire
- Friendswood
- Houston
- Wichita Falls
- Clinton
- Draper
- Rutland
- Charlottesville
- Seattle
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Levomecor Inc.
Does this study involve medication?
Yes. The study involves medication, including REL-1017 and Placebo.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
